This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

Claim 1 (currently amended): A ~~pharmaceutical composition~~ method for the prevention of alloimmunisation of a subject~~, said composition~~ comprising administering to the subject an immunologically effective epitope of a rhesus protein ~~or an immunologically active analogue or derivative thereof~~.

Claim 2 (currently amended): A ~~pharmaceutical composition~~ method for the immunosuppression of a response elicited by alloimmunisation of a subject ~~or an autoimmune haemolytic disease, said composition~~ comprising administering to the subject an immunologically effective epitope of a rhesus protein ~~or an immunologically active analogue or derivative thereof~~.

Claim 3 (canceled)

Claim 4 (currently amended): A ~~pharmaceutical composition~~ method according to ~~any preceding~~ claim 1 or 2 wherein the rhesus protein is either RhD, RhC, Rhc, RhE, or Rhe protein.

Claim 5 (currently amended): A ~~pharmaceutical composition~~ method according to ~~claim 4 comprising an~~ claim 1 or 2 wherein the epitope is selected from at least one of SEQ ID numbers 2, 5, 6, ~~6A, 10A,~~ 11, ~~11A,~~ 12, ~~12A,~~ 14, ~~15A, 18A,~~ 28, 29, 31, 38, ~~and~~ 39, 44, 47, 50, 51, 66, 75, 77, 78, 79, 81 and 84 ~~hereinbefore set forth~~.

Claim 6 (currently amended): A ~~pharmaceutical composition~~ method according to ~~either claims 4 or 5~~ claim 5 wherein the epitope is ~~either epitope 12A when alloimmunisation has occurred; or epitope 29 for autoimmune haemolytic anaemia~~ SEQ ID NO:79.

Claim 7 (currently amended): A ~~pharmaceutical composition~~ method according to ~~any preceding~~ claim 1 or 2 wherein the epitope or immunoreactive derivative is synthesised.

Claim 8 (currently amended): A ~~pharmaceutical composition for the induction of alloimmunisation of a subject, said composition comprising an immunologically effective epitope of a rhesus protein or an immunologically active analogue or derivative thereof~~ method of claim 1 or 2 wherein the epitope is disposed in a pharmacologically acceptable vehicle.

Claim 9-11 (canceled)

Claim 12 (currently amended): A ~~pharmaceutical composition~~ method according to ~~any of claims 8 to 11~~ claim 8 wherein the vehicle is selected such that the composition is in an injectable, oral, rectal, topical or spray-uptake form.

Claim 13-15 (canceled)

Claim 16 (currently amended): A ~~tolerising peptide fragment according to any of claims 13 to 15~~ method according to claim 8 wherein the pharmaceutically acceptable vehicle is adapted for transdermal or transmucosal administration or wherein said vehicle is a formulation with an enteric coating for oral administration.

Claim 17-18 (canceled)

Claim 19 (currently amended): ~~The use in the manufacture of a medicament~~ A method for the tolerisation of a patient who may become alloimmunised comprising administering an epitope selected from a RhD, RhC, Rhc, RhE or Rhe protein or selected from at least one of ~~epitope~~ SEQ

ID numbers 2, 5, 6, ~~6A, 10A,~~ 11, 11A, 12, ~~12A,~~ 14, ~~15A, 18A,~~ 28, 29, 31, 38, ~~and~~ 39, 44, 47, 50, 51, 66, 75, 77, 78, 79, 81 and 84 ~~hereinbefore set forth~~, and a pharmaceutically acceptable vehicle therefor.

Claim 20 (currently amended): ~~The use in the manufacture of a medicament~~ A method for the immunosuppression of an alloimmunised patient ~~or a patient with warm type autoimmune haemolytic anaemia~~ comprising administering an epitope selected from a RhD, RhC, Rhc, RhE or Rhe protein or selected from at least one of ~~epitope~~ SEQ ID numbers 2, 5, 6, ~~6A, 10A,~~ 11, 11A, 12, ~~12A,~~ 14, ~~15A, 18A,~~ 28, 29, 31, 38, ~~and~~ 39, 44, 47, 50, 51, 66, 75, 77, 78, 79, 81 and 84 ~~hereinbefore set forth~~, and a pharmaceutically acceptable vehicle therefor.

Claim 21 (currently amended): ~~The use~~ A method according to either claim 19 or 20 wherein the vehicle is adapted for transdermal or transmucosal administration.

Claim 22 (currently amended): A method for determining effect of one or more epitopes from a rhesus protein on a human lymphocyte, *in vitro*, comprising:

(a) stimulating the lymphocyte with one or more epitope/peptide of a rhesus protein;

(b) between 4 to 7 days later resuspending the cultures and transferring aliquots into plates prepared in the following manner:

(c) coating each well in the plate with monoclonal anticytokine capture antibody;

(d) washing the plate at least once with Hanks Buffered Salt Solution (HBSS);

(e) blocking any non-specific binding using an appropriate solution;

(f) incubating the plates with lymphocyte culture for 12-36 hours at 30-40°C in an atmosphere of substantially 5% CO_2 and substantially 95% air;

(g) washing the plates at least once with Tween/PBS;

(h) introducing an appropriate ~~biotinylates~~ biotinylated monoclonal detection antibody to each well and incubating for 30-60 mins at room temperature;

(i) washing the plates at least once with Tween/PBS;

(j) introducing of ExtrAvidin-alkaline phosphatase conjugate and incubating for 15-45 mins;

(k) washing the plates at least once with Tween/PBS;

(l) developing the plates with 50-150 µl per well of p-nitrophenyl phosphate in 0.05M carbonate alkaline buffer pH 9.6 added to each well; and

(m) reading the absorbance at 405 nm.

Claim 23 (canceled)